Efficacy and Safety of Dolutegravir + Lamivudine in Antiretroviral Treatment-naive Adults With HIV-1 Infection in a Multicenter Real-life Cohort Study
Latest Information Update: 20 Nov 2023
At a glance
- Drugs Dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms REDOLA
- 13 Nov 2023 Status changed from recruiting to completed.
- 26 Oct 2022 Results of retrospective real-life cohorts (n=185) assessing 96 weeks effectiveness and tolerability of Dolutegravir/lamivudine in naive patients, presented at the 16th International Congress on Drug Therapy and HIV Infection.
- 05 Apr 2021 Planned primary completion date changed from 15 Jan 2021 to 15 Jun 2021.